Abstract
Objective-To determine whether one week's drug treatment is sufficient to eradicate Helicobacter pylori in patients with duodenal ulcer.
Design-Single blind, randomised controlled trial. Setting-Specialised ulcer clinic in a teaching hospital.
Patients-155 patients with H pylori and a duodenal ulcer verified endoscopically which had either bled within the previous 24 hours or was causing dyspepsia.
Interventions-Patients were allocated randomly to receive either omeprazole for four weeks plus bismuth 120 mg, tetracycline 500 mg, and metronidazole 400 mg (all four times a day) for the first week (n=78), or omeprazole alone for four weeks (n=77). Further endoscopy was performed four weeks after cessation of all drugs.
Main outcome measures-Presence or absence of H pylori (by urease testing, microscopy, and culture of antral biopsy specimens), duodenal ulcer, and side effects.
Results-Eradication of H pylori occurred in 70 (95%) patients taking the four drugs (95% confidence interval 86% to 97%) compared with three (4%) patients taking omeprazole alone (1% to 11%). Duodenal ulcers were found in four (5%) patients taking the four drugs (2% to 12%) and in 16 (22%) patients taking omeprazole alone (14% to 32%). Mild dizziness was the only reported side effect (six patients in each group) and did not affect compliance.
Conclusions-A one week regimen of bismuth, tetracycline, and metronidazole is safe and effective in eradicating H pylori and reduces the number of duodenal ulcers four weeks after completing treatment.
Introduction
The linking of relapse of duodenal ulcers with Helicobacter pylori has been a considerable advance in managing patients with ulcer disease. Several studies have shown that in patients with duodenal ulcer and H pylori eradication of H pylori during ulcer healing is followed by duodenal ulcer relapse in only 5-10% of patients after one year compared with around 85% relapse in patients without eradication.`3 The most effective regimens against H pylori usually consist of three drugs taken three to four times a day for between two and six weeks. ' but the trend was not significant (table II) . Table II also shows the H pylon' status of the 20 patients with duodenal ulcer at follow up. Data on ingestion ofnon-steroidal anti-inflammatory drugs were available for all patients who had bled from their duodenal ulcer. Eight patients (14%) who were positive for H pylori were taking these drugs at the time of their bleed compared with three (14%) who were negative for Hpylon. Of the eight who were positive for H pylon, four were randomised to each group. All four patients given all four drugs became negative for H pylon compared with one patient given omeprazole. No patient taking non-steroidal anti-inflammatory drugs on admission had a duodenal ulcer at follow up.
Discussion
This trial provides good evidence that one week of bismuth, metronidazole, and tetracycline, in conjunction with omeprazole, is sufficient to eradicate H pylon in most patients. Our choice of drugs was based on current evidence indicating that the most effective regimens consist of bismuth, metronidazole, and either tetracycline or amoxycillin.4 Possible hypersensitivity to amoxycillin made us choose tetracycline. A tetracycline derivative, doxycycline, was considered as it can be given twice daily and penetrates tissue better, but it seems to be less effective than tetracycline in eradicating H pylorii. The only side effect experienced was dizziness. As it occurred with equal frequency in both groups and is a recognised side effect of omeprazole' we attributed it to this drug, although a placebo effect is also possible.
The duration of treatment to eradicate H pylori has become progressively shorter since the first reports, in which six weeks' combination treatment was given.' The current consensus suggests that two weeks' treatment is sufficient,4 but reports vary as to whether treatment against H pylori is given during the first or last fortnight of concomitant treatment with drugs to suppress acid secretion. We chose to give drugs active against H pylori during the first week of treatment for the sake of simplicity for the patient. Logan et al have reported experience of a one week regimen (bismuth, amoxycillin, metronidazole) in a heterogeneous group of patients (with duodenal ulcer, non-ulcer dyspepsia, and gastric ulcer). The 16 duodenal ulcers found on follow up in 72 patients treated with omeprazole alone seems unexpectedly high. Normally omeprazole will heal around 95% of duodenal ulcers with four weeks of treatment. The likely explanation is that most patients' ulcers were healed, but as they had endoscopy four weeks after omeprazole was stopped, these ulcers represent early recurrences. A similar finding occurred in a study by Marshall et al, in which ranitidine gave unexpectedly low rates of healing; the authors argued that the ulcers were most likely to be recurrences. We found far fewer ulcers in patients who had taken all four drugs. Eradication ofHpylori seems to reduce early recurrence of duodenal ulcer, as well as recurrence over a longer one year follow up, as noted in previous trials. 
Patients, methods, and results
The study was carried out in 20 lupus anticoagulant negative women aged 26-43 (mean 33) years with two or more (range 2-4, mean 2 6) fetal losses occurring in the first (76%) or second (24%) trimester. We also studied 18 lupus anticoagulant positive women aged 23-41 (mean 31) years with two or more (range 2-6, mean 3) fetal losses occurring in the first (71%) or second (29%) trimester.
Patients were screened for systemic diseases, diabetes mellitus, chromosome abnormalities in a parent, uterine abnormalities, and endometrial or hormonal luteal phase defects. Thirteen of the lupus anticoagulant positive patients had systemic lupus erythematosus, diagnosed according to American
